Pfizer's last quarter reflected ongoing drag from generic competition, and so the drugmaker keeps whittling away at costs where it can. The latest is its manufacturing operations in Puerto Rico, which have already been slimmed down in recent years.
Combination cancer therapies are all the rage these days in the oncology field. Now two of the giant players in the cancer R&D arena have decided to match their top prospects to see if they can make a bigger impact on melanoma.
Pfizer continues to suffer from post-patent revenue issues and so continues to close plants to balance its manufacturing needs. The next plant in line to close is a facility in Puerto Rico.
Why do Russians prefer cats to dogs? Which livestock drugs are growing fastest? And what are the benefits of being separate from Pfizer?
BlackBerry phones are a defining tech of the first decade of the 21st Century, a time when suited Big Pharma execs used the devices to facilitate multi-billion dollar takeovers. At Pfizer, the mega-merger era it helped create is over, and now its relationship with BlackBerry is coming to a close, too.
When Pfizer came to set up its Twitter account in 2009, the social network was already a big deal, with users sending 100,000 tweets per hour when Michael Jackson died. Arriving late to the party meant the @Pfizer handle was already taken. Now, four years later, Pfizer has finally claimed the account.
Pfizer, which sells the hemophilia drug Xyntha, last year rolled out its HemMobile app to build its relationship with patients who use its treatments. The fact that Pfizer didn't include a version for the BlackBerry goes a long way to explaining why the drug giant is asking its own remaining Blackberry users to turn in those phones.
On the heels of new guidelines casting doubts on a much-hyped new class of cholesterol drugs, the FDA said it would not demand long and costly outcomes trials before approving PCSK9 treatments from the likes of Amgen, Sanofi and Regeneron, clearing the way for treatments expected to rake in up to $3 billion a year.
The Massachusetts Attorney General's Office took Pfizer ($PFE) and Mylan Specialty to task for an ad that they said went too far in promoting how effective the EpiPen is in treating major allergic reactions. The Boston Business Journal reported that Pfizer, which makes the product, and Mylan Specialty, which markets it under license, must pay a $625,000 fine to settle charges in the case.
With Sanofi having already begun enrollment for its 15,000-person Phase III trial, the French company has a clear lead in the race to develop a Clostridium difficile vaccine, but a growing pack is in pursuit. The latest to give chase is a group of European scientists with a new angle--they are developing an oral vaccine.